{
    "clinical_study": {
        "@rank": "30043", 
        "arm_group": [
            {
                "arm_group_label": "MCI-196 (Flexible dose)", 
                "arm_group_type": "Experimental", 
                "description": "MCI-196 BSA eq 3g, 6g, 9g, 12g or 15g"
            }, 
            {
                "arm_group_label": "CBPB", 
                "arm_group_type": "Active Comparator", 
                "description": "Calcium-based P binder"
            }
        ], 
        "brief_summary": {
            "textblock": "The Primary Objectives of this study are to assess the long-term efficacy of treatment with\n      colestilan (MCI-196) (including combination therapy) and to assess the long-term safety of\n      treatment with colestilan (MCI-196) (including combination therapy)."
        }, 
        "brief_title": "Long-term Extension Study of MCI-196", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Kidney Disease", 
            "Dialysis", 
            "Hyperphosphatemia", 
            "Paediatric"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Hyperphosphatemia", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject and/or parent(s)/guardian(s) must be capable of providing informed\n             consent, and assent when applicable, in agreement with regional requirements.\n\n          -  The subject has completed either of the short-term studies, MCI-196-E14 or\n             MCI-196-E16\n\n        or\n\n          -  The subject has been withdrawn from MCI-196-E14, but is eligible to enter this study\n             according to the following rules, as defined in MCI-196-E14:\n\n               -  Hyperphosphataemia: Subjects who experienced hyperphosphataemia, defined as any\n                  increase in serum phosphorus [P] levels above the age-related upper limit of\n                  normal(ULN) on two consecutive occasions, and was withdrawn by the Investigator\n                  in order to proceed to this study, where flexible dosing with colestilan\n                  (MCI-196) is available. Subjects withdrawn from MCI-196-E14 due to\n                  hyperphosphataemia may only enter this study after Week 6 of the short-term\n                  study, following two consecutive out-of-range P values (one obtained at Week 3\n                  and one obtained at Week 6). After Week 6, subjects meeting the above criteria\n                  may enter this study at any time (the two consecutive out-of-range P values\n                  having been obtained any time after Week 6 from a scheduled or unscheduled\n                  visit).\n\n               -  Hypercalcaemia: Subjects treated with CBPB and experiencing hypercalcaemia may\n                  be withdrawn from the short-term study at the discretion of the Investigator in\n                  order to proceed to this study at any time, where flexible dosing with\n                  colestilan (MCI-196) is available.\n\n        Exclusion Criteria:\n\n          -  The subject has current clinically significant medical co-morbidities, which may\n             substantially compromise subject safety, or expose them to undue risk, or interfere\n             significantly with study procedures and which, in the opinion of the Investigator,\n             make the subject unsuitable for inclusion in the study (e.g., the subject currently\n             has or has had a history of seizure disorders, dysphagia, swallowing disorders,\n             predisposition to or current bowel obstruction, ileus or severe gastrointestinal [GI]\n             disorders such as chronic or severe constipation [as judged by the Investigator],\n             intestinal stenosis, intestinal diverticulum, sigmoid colitis, GI ulcers, current or\n             a history of GI bleeding, or major GI tract surgery).\n\n          -  The subject is expected to receive immunosuppressant treatment during the course of\n             the study.\n\n          -  The subject is considered unstable on his/her current treatment for CKD within one\n             month prior to enrolment (e.g., subjects starting treatment with vitamin D or its\n             analogues, or other agents/procedures that may influence bone mineral metabolism\n             [i.e., serum P and calcium (Ca) levels]).\n\n          -  The subject is considered to be non-compliant with study procedures in the opinion of\n             the Investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814917", 
            "org_study_id": "MCI-196-E15"
        }, 
        "intervention": [
            {
                "arm_group_label": "MCI-196 (Flexible dose)", 
                "description": "body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day", 
                "intervention_name": "colestilan", 
                "intervention_type": "Drug", 
                "other_name": "BindRen"
            }, 
            {
                "arm_group_label": "CBPB", 
                "intervention_name": "CBPB", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom"
                }, 
                "name": "Investigational site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-centre, Flexible Dose, Parallel Group, Open-label, Active Control (Calcium-based Phosphate Binder), Long-term Extension Study Evaluating the Efficacy, Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects With Hyperphosphataemia and With Either Chronic Kidney Disease Stage 5 on Dialysis or Chronic Kidney Disease Stages 3b to 5 Not on Dialysis", 
        "overall_contact": {
            "email": "cti-inq-ml@ml.mt-pharma.co.jp", 
            "last_name": "Clinical Trials Information Desk"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Turkey: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Kidney Disease Outcomes Quality Initiative (KDOQI)", 
            "measure": "Proportion of responders (responders are defined as subjects demonstrating serum P levels \u22641.5 SD above the KDOQI 2008 age-related mean value)", 
            "safety_issue": "No", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814917"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean absolute change in efficacy laboratory parameters (i.e.,P, Ca, Ca P ion product [CaxP], intact parathyroid hormone [iPTH], serum glucose, glycosylated haemoglobin [HbA1c], and uric acid)", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Mean percentage change in other efficacy laboratory parameters (i.e., lipid parameters [low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), total cholesterol, and triglycerides (TG)])", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }
        ], 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}